藥師幫周線八連陽後整固蓄勢 基本面紮實獲機構看好
經歷持續兩個月的強勢上升後,藥師幫(9885.HK)股價於6月9日-11日在10-11港元區間展開整固。此前,其股價年內累計最大升幅超120%,市值回升至70億港元以上。市場觀點認為,短期快速上升後,個股或存在震盪消化的需求,具備良好業績支撐的公司有望在調整後企穩並走出獨立行情。今年以來,藥師幫持續釋放多個利好。2024年實現全面扭虧為盈,經調淨利潤1.57億元,同比增20.1%。高毛利業務增長提速,今年1-4月廠牌首推業務成交規模達7.17億元,同比增長108.1%。公司基本面改善勢頭明顯,盈利邏輯得到充分驗證。同時,緊跟未來藥店業態升級趨勢,公司積極佈局前沿領域。6月3日,藥師幫與協作機器人龍頭越疆科技達成戰略合作,以醫藥協作機器人、AI大模型、藥品物聯網三大技術切入新零售場景,進一步發掘面向零售藥店的高附加值業務。公司的優質屬性吸引了機構高度關注。近期,長城證券、天風證券均給予“買入”評級,信達證券持更樂觀態度,預計24-27年間其歸母淨利潤複合增速有望達145%。公司管理層亦以實際行動彰顯信心,於2025年5月啟動億元回購計劃。根據公吿,藥師幫已於5月7日--6月11日連續回購543.5萬股,總回購金額超4231萬港元。回購均價持續走高。公司執行董事陳飛也於6月11日增持5萬股,年內累計增持80萬股,金額超627.3萬元。當前,港股醫藥板塊持續活躍,醫藥賽道成為資金主攻方向。政策面亦有多重紅利釋放,6月10日中辦、國辦發文允許在粵港澳大灣區企業“H+A”兩地上市,新一輪行情呼之欲出。業內普遍認為,藥師幫基本面向好、長期邏輯堅實,股價短期企穩屬於健康整固過程,將為下一波上升提供動力,有望進一步打開向上空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.